USP7 and chronic myelogenous leukemia, BCR-ABL1 positive: Interestingly, P22077 not only targets USP7 but also addresses IM resistance in CML by inhibiting USP47, enhancing the effectiveness against TKI-resistant CML cells and reducing Lin−Sca1+c-Kit+ CML stem/progenitor cell numbers in CML models [154].